Our brands:
Where tech meets bio.
Built newsletter-first and LinkedIn-first, anchored to an institutional brand — and engineered for how AI answer-engines surface authority (GEO), not legacy search. We reach a concentrated audience of techbio decision-makers where they already read.
A concentrated techbio audience.
One institutional brand, four ways to reach the industry.
A permanent analytical anchor, two flagship newsletters, and a high-velocity LinkedIn presence — a portfolio built to reach techbio buyers, builders, and investors wherever they read.
BioPharmaTrend
Flagship platformThe institutional intelligence platform — permanent, definitive analysis of AI in drug discovery and pharma R&D. The anchor the whole brand is built on.
Where Tech Meets Bio
NewsletterWeekly Substack deep dives into AI drug discovery, computational biology, and pharma R&D transformation — the weekly synthesis for the field.
The Biotech Edge
NewsletterCurated weekly intelligence on AI in drug discovery and competitive dynamics, delivered to industry professionals on LinkedIn.
LinkedIn Community
SocialFast, high-velocity analysis and industry takes across three channels — the velocity layer that keeps the brand in the daily conversation.
Two audiences. Two ways to work with us.
Reach the techbio market
Put your platform in front of a concentrated audience of pharma R&D leaders, biotech founders, and investors. Newsletter and LinkedIn sponsorships, lead-gen webinars, and co-branded reports.
Explore Media & Partnerships →Make sense of the frontier
Landscape intelligence and flagship analytical reports for investors, corporate strategy, and scouting teams navigating AI-driven transformation in drug discovery, pharma, and healthcare.
Explore Research & Intelligence →